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Background/Objectives: Lymphomatoid papulosis (LyP) is a cutaneous CD30þ lymphoproliferative dis-
order characterized by recurrent, self-healing lesions with a chronic clinical course. Approximately
10e20% of the patients have lymphomas, including mycosis fungoides (MF). LyP in association with MF is
not well documented in Taiwan. We aimed to describe the clinicopathologic characteristics of LyP with
MF in a Taiwanese case series of LyP.
Methods: A retrospective clinicopathologic studywas performed on cases of LyPwithMF diagnosed in our
Department during the period 1990e2012. The diagnosis of LyP andMFwere based on their characteristic
clinical and pathologic features as well as correlation with the clinical course of the speciﬁc skin lesions.
Results: A total of 24 cases of LyP (10 males and 14 females, age 18e63 years, mean 40.4 years) were
included. Multiple biopsies were often done in individual patients during the clinical course to establish
the diagnosis of LyP and MF. LyP was further classiﬁed pathologically as type A (n ¼ 16), B (n ¼ 3), C
(n ¼ 3), and mixed type with A&B (n ¼ 1) and A&C (n ¼ 1). Five cases (21%) also had MF; two had
juvenile-onset LyP and three had juvenile-onset MF (one with hypopigmented MF, one with hyperpig-
mented MF, two with CD8þ LyP, and two with CD8þ MF). In the case of juvenile-onset hypopigmented
CD8þ MF, the patient developed CD8þ LyP 25 years after the onset of MF and died of aggressive epi-
dermotropic CD8þ lymphoma involving the skin and lung.
Conclusion: MF occurred in ﬁve of the 24 cases (21%) in the present series of LyP. These ﬁve cases had
several unusual clinical and pathologic features, including subtle or uncommon skin manifestation of MF
and more frequent juvenile-onset and CD8 phenotype of LyP and/or MF lesions. Long-term follow-up and
repeated biopsy of selected skin lesions are necessary for correct diagnosis and proper treatment of both
diseases.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Primary cutaneous CD30þ lymphoproliferative disorders (PC-
CD30þLPDs) are the second most common group of cutaneous T-
cell lymphomas (CTCLs), next to mycosis fungoides (MF), and ac-
count for about 30% of CTCLs.1 The spectrum of PC-CD30þLPDs
comprises primary cutaneous anaplastic large cell lymphoma (C-
ALCL), lymphomatoid papulosis (LyP), and borderline cases.y have no ﬁnancial or non-
tter or materials discussed in
logy, National Cheng Kung
Li Road, Tainan 704, Taiwan.
e).
iwanese Dermatological AssociatioLyP is a chronic, recurrent, self-healing papulonodular or pap-
ulonecrotic skin disease with inﬁltration of atypical CD30þ lym-
phocytes histologically. Clinically, the skin lesions of LyP typically
wax and wane with spontaneous resolution in 3e12 weeks. The
histologic ﬁndings of LyP are variable and three histologic subtypes
(types A, B, and C) have been recognized with overlapping features;
all three types may be observed in the same patient. Moreover, the
age of the individual skin lesion at the time of biopsy also con-
tributes to variability of histopathologic ﬁndings.
LyP type A (histiocytic) lesions are characterized by inﬁltration
of scattered or small clusters of large, sometimes multinucleated, or
Reed-Sternberg-like CD30þ cells intermingled with numerous in-
ﬂammatory cells, such as histiocytes, small lymphocytes, neutro-
phils, and/or eosinophils. LyP type C (ALCL-like) lesions
demonstrate a monotonous population or large clusters of large
CD30þ T cells with relatively few inﬂammatory cells. LyP type Bn. Published by Elsevier Taiwan LLC. All rights reserved.
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epidermotropic inﬁltrate of small atypical lymphocytes with cere-
briform nuclei similar to that seen in MF.
Twonewvariants of LyPhave recentlybeendescribed.2,3 LyP type
D is characterized histopathologically by inﬁltration of medium-
sized, CD8þ/CD30þ pleomorphic, atypical, lymphocytes with
marked epidermotropism in a pagetoid reticulosis-like pattern,
mimicking primary cutaneous aggressive epidermotropic CD8þ
cytotoxic T-cell lymphoma. LyP type E is characterized by self-
healing, oligolesional papulonodules with necrotic eschar clini-
cally, and an angiocentric/angiodestructive inﬁltrate of small- to
medium-sized CD30þ, and frequently CD8þ, atypical lymphocytes.
In up to 20% of patients, LyP may be preceded by, associated
with, or followed by malignant lymphomas, with MF, Hodgkin’s
disease, and CD30þ large cell lymphomas comprising 90% of the
associated lymphomas.1 In patients with LyP associated with MF,
including three of 15 cases in the study by Basarab et al,4 and two
cases each by Wood et al5 and Chott et al,6 identical clones have
been reported in both types of lesions.
Reports of MF in association with LyP from Taiwan are rare.7,8 In
this study, we aim to describe the clinicopathologic characteristics
of cases of LyP with MF affecting Taiwanese.Materials and methods
Cases of LyP diagnosed during the period 1990e2012 in the
Department of Dermatology, National Cheng Kung University Hos-
pitalwere retrieved fromtheDepartment’s Cruxdatabase system. In
each case, the medical record, clinical photos, and pathology slides
were reviewed. Speciﬁcally, the morphology (papules, nodules,
patches, or plaques), onset anddistributionof skin lesions, evolution
of individual lesions (waxing and waning versus persistent) as well
as the overall clinical course and treatment responsewere analyzed.
Follow-up data were obtained from medical records, the Crux
database, or via telephone contact with patients. All skin biopsyTable 1 Clinical and pathologic features of a series of 24 lymphomatoid papulosis (LyP)
Patient Sex/age of
diagnosis (y)
LyP lesions Distribution Type/T-cell type As
lym
1 M/18 P/N G A&B MF
2 F/36 P/N L (lower extremities) B MF
3 M/32 P/N L (upper extremities) A MF
4 M/37 P/N G A MF
T-c
5 F/31 P/N G A&C MF
6 M/55 P/N G A d
7 F/55 P/U G A d
8 F/50 P/N G A d
9 F/32 P/N G A d
10 F/31 P/U G A d
11 F/48 P/N G A d
12 F/49 P/U G C d
13 M/55 P/U L (penis) A d
14 M/42 P/N G B d
15 F/43 P/N G A d
16 M/36 P/N G A d
17 F/33 P/N L (extremities) A d
18 M/41 P/N G B d
19 F/18 P/N G A d
20 F/42 P/U G C d
21 M/35 P/N L (lower extremities) A d
22 M/48 P/U G C d
23 F/63 P/U G A d
24 F/42 P/N/U L (extremities) A d
F ¼ female; G ¼ generalized; L ¼ localized; M ¼ male; MF ¼ mycosis fungoides; MTX ¼
PUVA ¼ psoralen ultraviolet A; U ¼ ulcer; UVB ¼ ultraviolet B.
a Under control: new lesions can be suppressed, only sporative small new papules pospecimens were processed for routine histopathologic study. LyP
lesions were classiﬁed as type A, B, or C based on the features
delineated in the literature. Immunohistochemical stainings for CD3
(DakoCytomation Denmark A/S, Denmark), CD4 (BioSB, USA), CD8
(DakoCytomation Denmark A/S, Denmark), CD20 (DakoCytomation
Denmark A/S, Denmark), CD30 (Dako Denmark A/S, Denmark), and
granzyme B (Fremont, CA, USA) were performed in selected cases.
Results
Clinical presentations, clinical course, histology, and treatment
There were a total of 24 cases of LyP, consisting of 10 males and 14
females with age ranging from 18 years to 63 years (mean 40.4
years). Three patients had juvenile-onset LyP (deﬁned by disease
onset before 18 years of age). The LyP lesions were papulonodules,
some with crusted or necrotic centers. The skin lesions were
widespread over the limbs and trunk in 18 patients (75%) and were
more limited to the limbs and/or penis in six patients. Most of the
LyP lesions waxed and waned, lasting for about 1 week in smaller
lesions or up to 1 month in larger lesions. The clinical and patho-
logic features were summarized in Table 1. Of the 24 cases, LyP was
classiﬁed as type A in 16 (67%), type B in three (13%), type C in three
(13%), and two cases hadmore than one type: Case 1with both type
A and type B lesions, and Case 5with both type A and type C lesions.
Of these 24 patients, ﬁve (21%) also had MF and their LyP was
type A in three (60%), type B in one (20%), and mixed type A þ B in
one (20%). The clinical presentations of these ﬁve cases are sum-
marized in Table 2 and brieﬂy described as follows.
Case 1
The patient was an 18-year-old male who had concurrent onset of
both LyP andMF at 9 years of age. He ﬁrst presented to us at the age
of 18 years with a 9-year history of recurrent, self-healingcases.
sociated
phoma
Follow-up
(mo)
Main therapy Outcomea
49 MTX Under control
45 UVB311 Under control
2 MTX Under control
; peripheral
ell lymphoma
108 Systemic retinoids, CHOP Death due to systemic
involvement
302 PUVA, topical steroids Under control
0.5 obs N/A
d N/A N/A
3 UVB Under control
10 MTX Under control
d N/A N/A
1 UVB311 Under control
0.5 MTX Under control
3 Topical steroids Subsided
165 Neotigason Under control
7 Topical steroids, obs Under control
0.5 Topical steroids, obs Under control
2 Topical steroids Under control
302 MTX Under control
12 Topical steroids Under control
36 MTX Under control
d N/A N/A
8 MTX Under control
d N/A N/A
d N/A N/A
methotrexate; N ¼ nodule; N/A ¼ not applicable; obs ¼ observation; P ¼ papule;
pped out.
Table 2 Summary of ﬁve cases of lymphomatoid papulosis (LyP) with mycosis fungoides (MF).
Patient/age
(y)/sex
LyP: extent of
lesions/type
MF: extent of lesions/type
of skin lesions
Onset of
LyP (y)
Onset of
MF (y)
Other lymphoma Effective treatment
1/18/M G/A, B (CD8þ) L/patch/plaque (CD8þ) 9 9 d MTX for LyP
2/34/F L/B G/hyperpigmented patch 13 16 d UVB311 for MF
3/32/M L/A L/patch 31 29 d MTX for LyP
4/37/M G/A (CD8þ) G/hypo-pigmented patch (CD8þ) 37 12 CD8þ epidermotropic
lymphoma
No regular treatments
5/31/F G/A, C L/reticulate brown patch 27 32 d PUVA and topical steroids
A¼ LyP type A; B¼ LyP type B; C¼ LyP type C; G¼ generalized; F¼ female; L¼ localized; M¼male; MTX¼methotrexate; PUVA¼ psoralen ultraviolet A; UVB¼ ultraviolet B.
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(Figure 1A and B), and persistent patch/plaque lesions on the right
calf (Figure 1C). The papulonodular lesions waxed and waned and
some nodules would become necrotic with central eschar
(Figure 1B). He had six skin biopsies over a course of 28 months.
Upon correlating with the clinical course of the lesions, the lesions
were classiﬁed as LyP type A (1 specimen) (Figure 2A and B), LyP
type B (4 specimens,1 was a resolving lesion) (Figure 3A and B), and
MF (1 specimen) (Figure 4A and B). Marked epidermotropism of
lymphocytes was observed in all type B lesions. Angioinvasion was
noted in a type B lesion and the MF lesion (Figure 4B). The atypical
lymphocytes were CD8þ, CD30þ, EBER-1 (Epstein-Barr virus
encoded small RNA-1)e, and CD56e in the type A lesion and CD8þ,
CD30e, EBER-1e, and CD56e in the type B and MF lesions. Gran-
zyme B was expressed in 10e20% of the CD30þ large atypical cells
in the type A lesion. The patient also had some hypopigmented
patches of varying sizes on the right upper limb (Figure 1A).
Hypopigmented MF was suspected clinically, but was not
conﬁrmed pathologically. The LyP lesions in this patient did not
respond to ultraviolet B (UVB) 311 phototherapy, but were effec-
tively suppressed by low dose methotrexate (MTX) therapy (7.5 mg
per week) with only occasional small papules developed from time
to time during the follow-up period of 49 months.Figure 1 Clinical manifestation of Case 1. (A) An erythematous papule in a large hypopigm
central eschar on the right arm (pathology: LyP type A). (C) A persistent scaly plaque on thCase 2
The patient, a 34-year-old female, presented with an 18-year his-
tory of generalized hyperpigmented patches (Figure 5A). Biopsy of a
patch revealed changes of MF pathologically. With narrow band
UVB311 therapy, the MF lesions resolved (Figure 5B) in 1 year.
Approximately 1 year into her maintenance UVB therapy, we
noticed for the ﬁrst time a papule on her right lower leg (Figure 5C),
which was biopsied and then conﬁrmed to be LyP type B. She
recalled that she had similar, but more widespread, erythematous
papules since 13 years of age. The lesions wouldwax andwanewith
small papules resolving in about 2 weeks spontaneously, while
larger lesions would take a longer time. The LyP lesions were not
suppressed by UVB311 therapy and new lesions continued to
appear from time to time over a 42-month period while she was
receiving UVB therapy.Case 3
A 32-year-old male presented with a 1-year history of recurrent,
self-healing erythematous papules on the left arm. Biopsy of two
papules revealed changes of LyP type A. When the patient returned
1 week after skin biopsy, the popular lesions had mostly resolved.ented patch over the right arm (pathology: LyP type B). (B) An ulcerated nodule with
e right calf (pathology: mycosis fungoides). LyP ¼ lymphomatoid papulosis.
Figure 2 Pathological ﬁndings of LyP A Case 1. (A) A biopsy specimen of a LyP type A
lesion reveals a superﬁcial and deep, dense perivascular and peri-adnexal lymphocytic
inﬁltrate in the dermis containing numerous medium to large atypical lymphocytes
(hematoxylin and eosin; original magniﬁcation: 40). (B) The atypical
CD30þ lymphocytes in this inﬁltrate are highlighted by immunostaining (immuno-
peroxidase stain for CD30; original magniﬁcation: 400). LyP ¼ lymphomatoid
papulosis.
Figure 3 Pathological ﬁndings of LyP B in Case 1. (A) A biopsy specimen of a type B lesion
is characterized byprominent lymphocytic epidermotropismwith inﬁltration of atypical
lymphocytes at all levels of the epidermis, especially in the lower half (hematoxylin and
eosin; original magniﬁcation: 100). (B) Most of the intraepidermal lymphocytes are
CD8þ (immunoperoxidase stain for CD8þ; original magniﬁcation: 200).
LyP ¼ lymphomatoid papulosis.
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in the background skin. Another specimen was obtained from the
patch, which showed early changes of MF. He recalled that the
pigmented patch had been present for about 3 years. Both types of
lesions affected the same circumscribed area of the left upper arm.
The papular lesions were suppressed by low dose MTX treatment
(7.5 mg per week), but he stopped treatment 2 months later. Since
then, new papules would appear episodically in the same area and
then resolve in 2e3 weeks. The MF patch remained persistent
without obvious change during 3 years of follow-up.Case 4
This case, except the ﬁnal outcome, had been reported previously.7
Brieﬂy, the patient was a 37-year-old male when he ﬁrst visited us
in 1996 for a recurrent, self-healing ulcerative eruption. Examina-
tion revealed multiple 0.5e2 cm erythematous papules and nod-
ules with necrosis and ulceration on his trunk and extremities.
Biopsies of three separate lesions revealed changes consistent with
LyP type A (CD8þ). Apart from the LyP lesions, he also had multiplepersistent patches and plaques. He recalled that a persistent
hypopigmented patch was ﬁrst noted on his back at grade school.
Gradually, red plaques appeared within the white patch over time,
and additional plaques and patches developed elsewhere on the
trunk and proximal extremities. Biopsy specimens from two
persistent red scaly plaques within a large white patch on the right
upper extremity revealed changes of MF. The biopsy specimen from
thewhite patch on the back showed changes of the hypopigmented
MF with prominent lymphocytic epidermotropism. Immunostain-
ing of these three lesions revealed that the inﬁltrate consisted of
CD4þ and CD8þ lymphocytes, and that over 50% of the lympho-
cytes in the epidermis and up to 40% in the dermis were CD8þ.
He received systemic retinoids [etretinate or acitretin, 10 mg
three times a day (tid)] and subcutaneous interferon alpha-2b (3
million units, three times aweek) intermittently beginning in 1996.
In 1999, about 28 years after onset of MF, erythematous to
brownish inﬁltrating annular plaques began to appear on the ex-
tremities; most of these lesions developed central necrosis and
then healed in weeks. However, a large inﬁltrating plaque on the
left shin continued to grow and became ulcerated, covered by a
large black eschar. Biopsy of an annular plaque in 2005 showed
inﬁltration of atypical lymphocytes that were CD8þ but were
negative for CD4, CD30, CD56, and EBER-1. The ﬁndings were
consistent with CD8þ peripheral T-cell lymphoma. The necrotic
Figure 4 Pathological ﬁndings of MF in Case 1. (A) A biopsy specimen of a persistent
scaly lesion is characterized by psoriasiform hyperplasia with lymphocytic epi-
dermotropism with many single lymphocytes aligned along the basal layer (H&E;
original magniﬁcation: 200). (B) Angioinvasion in the MF lesion. There is a dense
inﬁltrate of atypical lymphocytes in the media with abundant ﬁbrin deposit in the
intima in a dermal blood vessel (H&E; original magniﬁcation: 400).
H&E ¼ hematoxylin and eosin; MF ¼ mycosis fungoides.
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lymphoma with fusariosis, and then systemic chemotherapy after
lung involvement by CD8þ lymphoma was detected in 2005. He
eventually died of metastasis and multiple organ failure after
several cycles of chemotherapy.
Case 5
The patient was a 31-year-old female who ﬁrst presented in 1997
with a generalized papulonodular eruption on the trunk and ex-
tremities. The eruption had been waxing and waning for 4 years.
She had eight biopsies between 1997 and 2007. The ﬁrst two bi-
opsies from two nodules revealed changes consistent with LyP type
A. Two more biopsy specimens were obtained from persistent
reticulated brownish lesions on both forearms in 2002 and showed
changes of MF. Four additional skin biopsies were performed and
revealed changes of LyP type A (2 specimens), type C (1 specimen),
and early or late lesion of LyP (1 specimen). No evidence of
extracutaneous lesions was detected by positron emission tomog-
raphy. The patient had been treated over a 15-year period, starting
with a low dose of MTX for about 4 months. Because the effect was
not satisfactory, she was then treated effectively with psoralen ul-
traviolet A (PUVA) therapy for the following years except for a 2-year period of acitretin therapy. With PUVA therapy, only small
numbers of new small papules would appear from time to time.
Discussion
In this report, we described 24 Taiwanese cases of LyP. Five (21%) of
them also had MF, a rate comparable to the 10e20% reported in the
literature.8,9 Of the ﬁve patients with LyP and MF, the LyP lesions
were type A&B, B, A, A, and A&C, respectively. The MF in three of
these patients had either subtle or unusual features clinically. One
manifested as a single persistent patch where LyP lesions colo-
calized, one as hyperpigmented variant and one as hypopigmented
variant. The onset of LyP and MF was concurrent in Case 1, and was
LyP or MF ﬁrst in the remaining four cases (Table 2). In Case 4, the
patient with hypopigmented CD8þ MF, the CD8þ LyP and aggres-
sive epidermotropic CD8þ lymphoma were fatal with pulmonary
involvement. Although the aggressive CD8þ lymphoma in this
patient could have been the result of malignant transformation of
his longstanding MF, the atypical cells in the CD8þ lymphoma did
not have the characteristics of MF with large cell transformation,
speciﬁcally, the atypical cells were not of large cell type and were
not CD30þ as commonly seen in lesions of MF with large cell
transformation. Moreover, the MF lesions on the trunk and prox-
imal extremities changed little over decades, while the inﬁltrative
annular plaques on the lower extremities showed obvious pro-
gression in a few years. Therefore, based on the pathological ﬁnd-
ings, the clinical features and clinical course of the lesions, the
aggressive CD8þ lymphoma in this patient was more likely to be a
separate lymphoma from the longstanding MF.
Reports of LyP associated with MF in Taiwan are limited. In a
recent series of 34 cases of LyP,10 the authors observed associated
lymphoma in two cases (6%), both with ALCL. There was no
mention of MF. In comparison, our series had a much higher rate of
MF. However, it should be pointed out that the MF lesions were
relatively subtle or of unusual presentation in our patients, and
such lesions could easily be overlooked or misdiagnosed clinically
and/or pathologically. Nonetheless, our effort in closemonitoring of
skin lesions clinically combined with repeated skin biopsy had
allowed us to make the diagnosis of MF in addition to LyP.
LyP had been reported only rarely in children.11e16 The clinical
picture and histopathology were similar to those in adults, but no
malignant transformation has been documented in childhood-
onset LyP, even if the disease carries on into adulthood.17 Of our
ﬁve cases with LyP and MF, Case 1 and Case 2 had juvenile onset of
LyP, and neither developed malignant transformation to ALCL 13
years and 25 years, respectively, after onset of LyP.
Another feature worth noting is that three of our patients with
LyP andMF (Cases 1, 2, and 4) had juvenile-onsetMF, and two of the
MF (Cases 1 and 4) was CD8þ, including a case of hypopigmented
MF (Case 4). Interestingly, the LyP was also CD8þ in the type B
lesion in Case 1 and in the type A lesion in Case 4. CD8þ is an
uncommon phenotype in MF with a reported rate of less than 5%.
However, this phenotype is more common in juvenile-onset MF, up
to 38% in a study of 34 cases with juvenile-onset MF.18 Notably, 71%
of the CD8þ MF cases in that series manifested hypopigmented
lesions. The over-representation of a cytotoxic phenotype in chil-
dren with MF had also been reported by others.19,20
Additional unusual features in the present study were the
ﬁndings of prominent epidermotropism and angioinvasion in Case
1. Prominent epidermotropism was observed in all of his biopsy
specimens of LyP type B and MF lesions, and angioinvasion was
noted in a type B lesion and the MF lesion. There are two newly
deﬁned variants for LyP, namely, type D and E.2,3 The type D variant
is characterized by CD30þ, CD8þ with marked epidermotropism
and the type E variant is characterized by CD30þ with
Figure 5 Clinical manifestation of Case 2 with hyperpigmented mycosis fungoides and lymphomatoid papulosis type B. (A) Multiple persistent hyperpigmented patches and thin
plaques are noted on the abdomen, and (B) the lesions resolved after 1 year of narrow band ultraviolet B311 therapy. (C) An erythematous papule is noted on the leg.
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lymphocytic epidermotropism as well as angioinvasion in LyP le-
sions in Case 1, the inﬁltrating lymphocytes were CD8-positive,
CD30-negative. Therefore, these lesions could not be classiﬁed as
type D or E of LyP.
The optimal treatment for LyP has not been established and
there is no evidence to suggest that the treatment can alter the
natural course or malignant transformation.21 Because LyP lesions
usually resolve spontaneously in 2e12 weeks, active treatment is
optional and is generally reserved for symptomatic relief and
cosmetic reasons. However, systemic agents or skin-directed
treatments may be warranted in generalized disease. Topical
treatment with carmustine, nitrogen mustard, MTX, imiquimod
cream,22 intralesional interferon, low-dose cyclophosphamide,
chlorambucil, medium-dose UVA-1 therapy, excimer laser ther-
apy,23 photodynamic therapy,24 and dapsone have been reported to
be helpful in disease suppression. Low-dose oral methotrexate (5e
20 mg/week) is the most effective therapy to suppress the devel-
opment of new skin lesions of LyP, but the disease often relapsed
within months in most series,25 and treatment of LyP did not
necessarily decrease the risk of development of a second hemato-
logical malignancy.26
For patients with concurrent MF and LyP, the patients can be
treated with a single agent therapy that is effective for both dis-
eases, including topical steroids, topical nitrogen mustard oint-
ment, oral weekly MTX, PUVA photochemotherapy, low dose
interferon alpha, oral bexarotene, and electron beam radiation
therapy.24 MF and LyP typically responded to therapy within 2e6
months. Topical steroids and nitrogen mustards are often only
modestly helpful for LyP, mostly for newly emerged lesions. PUVA
and systemic medications can suppress the formation of new le-
sions. For follow-up, some institutes recommended annual physical
examination or sooner, including palpation of lymph nodes, liver,spleen, and laboratory tests for relapsed/progressive disease.26
Patients with recurrent disease can undergo repeated courses of
PUVA phototherapy before moving onto an oncologic approach.26
Most of our patients with LyP and MF were treated with UVB,
PUVA, UVB311, MTX or topical steroids effectively, except one pa-
tient (Case 4) who did not receive regular treatment. He unfortu-
nately developed fatal epidermotropic CD8þ lymphoma of the skin
with pulmonary involvement years later.
Conclusion
MF was diagnosed in ﬁve cases (21%) among 24 cases of LyP
affecting Taiwanese. These ﬁve cases had several unusual clinical
and pathologic features, including subtle or uncommon skin
manifestation of MF, and more frequent juvenile onset and CD8
phenotype of LyP and/or MF. Long-term follow-up and repeated
biopsy of selected skin lesions are necessary for correct diagnosis
and proper treatment of both diseases.
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